These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 33429090)
41. Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of overactive bladder in elderly people: a triple-blinded randomized controlled trial. Jacomo RH; Alves AT; Lucio A; Garcia PA; Lorena DCR; de Sousa JB Clinics (Sao Paulo); 2020; 75():e1477. PubMed ID: 31939564 [TBL] [Abstract][Full Text] [Related]
42. Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy. Pincus J; Rostaminia G; Chang C; Gafni-Kane A; Goldberg RP Neurourol Urodyn; 2019 Aug; 38(6):1676-1684. PubMed ID: 31107570 [TBL] [Abstract][Full Text] [Related]
43. Self-management of overactive bladder at home using transcutaneous tibial nerve stimulation: a qualitative study of women's experiences. Daly CME; Loi L; Booth J; Saidan D; Guerrero K; Tyagi V BMC Womens Health; 2021 Oct; 21(1):374. PubMed ID: 34706709 [TBL] [Abstract][Full Text] [Related]
44. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. Perissinotto MC; DʼAncona CA; Lucio A; Campos RM; Abreu A J Wound Ostomy Continence Nurs; 2015; 42(1):94-9. PubMed ID: 25549314 [TBL] [Abstract][Full Text] [Related]
45. Different electrode positioning for transcutaneous electrical nerve stimulation in the treatment of urgency in women: a study protocol for a randomized controlled clinical trial. Padilha JF; Avila MA; Seidel EJ; Driusso P Trials; 2020 Feb; 21(1):166. PubMed ID: 32046754 [TBL] [Abstract][Full Text] [Related]
46. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Vecchioli-Scaldazza C; Morosetti C; Berouz A; Giannubilo W; Ferrara V Gynecol Obstet Invest; 2013; 75(4):230-4. PubMed ID: 23548260 [TBL] [Abstract][Full Text] [Related]
47. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Canbaz Kabay S; Kabay S; Mestan E; Cetiner M; Ayas S; Sevim M; Ozden H; Karaman HO Neurourol Urodyn; 2017 Jan; 36(1):104-110. PubMed ID: 26352904 [TBL] [Abstract][Full Text] [Related]
48. How I Do It: Transcutaneous tibial nerve stimulation TENSI+ system. Cornu JN; Hashim H; Van Der Aa F; De Nunzio C; Perez VG; Ferreira R; Elterman DS Can J Urol; 2023 Dec; 30(6):11756-11761. PubMed ID: 38104335 [TBL] [Abstract][Full Text] [Related]
49. Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome. Te Dorsthorst M; van Balken M; Janssen D; Heesakkers J; Martens F Ther Adv Urol; 2021; 13():17562872211041470. PubMed ID: 34484428 [TBL] [Abstract][Full Text] [Related]
50. Transcutaneous tibial nerve stimulation to treat urgency urinary incontinence in older women: 12-month follow-up of a randomized controlled trial. Schreiner L; Nygaard CC; Dos Santos TG; Knorst MR; da Silva Filho IG Int Urogynecol J; 2021 Mar; 32(3):687-693. PubMed ID: 33057739 [TBL] [Abstract][Full Text] [Related]
51. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786 [TBL] [Abstract][Full Text] [Related]
52. Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. Wang M; Jian Z; Ma Y; Jin X; Li H; Wang K Int Urogynecol J; 2020 Dec; 31(12):2457-2471. PubMed ID: 32681345 [TBL] [Abstract][Full Text] [Related]
53. Evaluating the effects of transcutaneous tibial nerve stimulation or pelvic floor muscle training on sexual dysfunction in female multiple sclerosis patients reporting overactive bladder. Polat Dunya C; Tülek Z; Kürtüncü M; Gündüz T; Panicker JN; Eraksoy M Neurourol Urodyn; 2021 Aug; 40(6):1661-1669. PubMed ID: 34174117 [TBL] [Abstract][Full Text] [Related]
54. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Manríquez V; Guzmán R; Naser M; Aguilera A; Narvaez S; Castro A; Swift S; Digesu GA Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():6-10. PubMed ID: 26645117 [TBL] [Abstract][Full Text] [Related]
56. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. Peters KM; Carrico DJ; Perez-Marrero RA; Khan AU; Wooldridge LS; Davis GL; Macdiarmid SA J Urol; 2010 Apr; 183(4):1438-43. PubMed ID: 20171677 [TBL] [Abstract][Full Text] [Related]
57. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541 [TBL] [Abstract][Full Text] [Related]
58. Parasacral versus tibial transcutaneous electrical stimulation to treat urinary urgency in adult women: Randomized controlled clinical trial. Falcão Padilha J; Arias Avila M; Driusso P Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():167-173. PubMed ID: 34773880 [TBL] [Abstract][Full Text] [Related]
59. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Vecchioli-Scaldazza C; Morosetti C Int Braz J Urol; 2018; 44(1):102-108. PubMed ID: 29064651 [TBL] [Abstract][Full Text] [Related]
60. Persistence in Percutaneous Tibial Nerve Stimulation Treatment for Overactive Bladder Syndrome is Best Predicted by Patient Global Impression of Improvement Rather Than Symptom-Specific Improvement. Brandon C; Oh C; Brucker BM; Rosenblum N; Ferrante KL; Smilen SW; Nitti VW; Pape DM Urology; 2021 Feb; 148():93-99. PubMed ID: 33358753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]